Navigation

pseudoephedrine (Sudafed, Nexafed, Zephrex-D)

 

Classes: Decongestants, Systemic

Dosing and uses of Sudafed, Nexafed (pseudoephedrine)

 

Adult dosage forms and strengths

tablet, immediate-release

  • 30mg
  • 60mg

tablet, extended-release

  • 120mg
  • 240mg

tablet, IMPEDE technology (Nexafed)

  • 30mg
  • IMPEDE technology utilizes an advanced polymer matrix to limit extraction of pseudoephedrine from tablets and deter methamphetamine manufacturing

tablet, TAREX technology (Zephrex-D)

  • 30mg
  • TAREX technology utilizes an advanced polymer matrix to limit extraction of pseudoephedrine from tablets and deter methamphetamine manufacturing

syrup

  • 3mg/mL

 

Nasal Congestion

Immediate release: 60 mg PO q4-6hr PRn

Extended release: 120 mg PO q12hr or 240 mg PO q24hr

 

Priapism (Off-label)

60-120 mg PO

 

Pediatric dosage forms and strengths

tablet, immediate-release

  • 30mg
  • 60mg
  • 120mg

tablet, extended-release

  • 120mg
  • 240mg

tablet, IMPEDE technology (Nexafed)

  • 30mg
  • IMPEDE technology utilizes an advanced polymer matrix to limit extraction of pseudoephedrine from tablets and deter methamphetamine manufacturing

tablet, TAREX technology (Zephrex-D)

  • 30mg
  • TAREX technology utilizes an advanced polymer matrix to limit extraction of pseudoephedrine from tablets and deter methamphetamine manufacturing

syrup

  • 3mg/mL

 

Nasal Congestion

<2 years: Safety and efficacy not established

2-6 years: 5-30 mg PO q4-6hr PRn

6-12 years: 30 mg PO q4-6hr, OR 4 mg/kg/day divided q6hr; not to exceed 120 mg/day

>12 years: 60 mg PO q6hr PRN (immediate release); alternatively, 120 mg PO q12hr (extended release) or 240 mg PO q24hr (extended release)

 

Dosing Considerations

Potential toxic dose <6 years: 11 mg/kg

 

Sudafed, Nexafed (pseudoephedrine) adverse (side) effects

Frequency not defined

Tremor

Restlessness

Insomnia

Nausea

Vomiting

Nervousness

Hypertension

Atrial fibrillation

Myocardial infarction

Ventricular premature beats

Ischemic colitis

 

Warnings

Contraindications

Hypersensitivity

Severe hypertension, severe CAd

Within 14 days of MAO inhibitor therapy

Newborns, preemies

Administration of extended release to patients <12 years

 

Cautions

Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, and glaucoma

Lactation

Elderly may be more sensitive to side effects

See health-care provider if symptoms do not improve within 7 days or are accompanied by fever

Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)

 

Pregnancy and lactation

Pregnancy category: C

Lactation: Concentrated in breast milk, Mfr contraindicates (AAP Committee states compatible with nursing)

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Sudafed, Nexafed (pseudoephedrine)

Mechanism of action

Alpha-adrenergic agonist of receptors present in respiratory mucosa, causing vasoconstriction; directly stimulates beta-adrenergic receptors and causes bronchial relaxation, as well as increased heart rate and contractility.

 

Duration

60 mg: 3-8 hr

120 mg: 12 hr

 

Absorption

Minimal systemic

Onset: 30 min (PO)

Peak plasma time: 1.97 hr

Concentration: 422 ng/mL

 

Metabolism

Liver, by N-demethylation

Metabolites: Inactive

 

Elimination

Half-life: 9-16 hr (adults; urine pH 8); 3-6 hr (adults; urine pH 5)

Clearance: 7.3-7.6 mL/min/kg

Excretion: Urine